¶ Overview
The atypical parkinsonian disorders — Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD) — share features with Parkinson's disease but exhibit distinct pathological mechanisms,更快 disease trajectories, and therapeutic responses. This page provides a comprehensive comparison of these three disorders.
¶ Overview
All three disorders exhibit:
- Parkinsonian features (bradykinesia, rigidity, tremor)
- Poor levodopa response (unlike classic PD)
- Additional neurological involvement (cortical, cerebellar, autonomic)
- Faster progression than typical PD
However, the underlying pathology and mechanisms differ substantially.
flowchart TD
subgraph "Alpha-Synucleinopathies"
MSA["MSA<br/>(Oligodendrogliopathy)"]
PD["PD<br/>(Neuronopathy)"]
DLB["DLB<br/>(Neuronopathy)"]
end
subgraph "Tauopathies"
PSP["PSP<br/>(4R Tau)"]
CBD["CBD<br/>(4R Tau)"]
end
MSA -.-> PD
MSA -.-> DLB
PSP -.-> CBD
style MSA fill:#e1f5fe,stroke:#333
style PSP fill:#f3e5f5,stroke:#333
style CBD fill:#fff3e0,stroke:#333
¶ Pathological Classification
| Disorder | Primary Protein | Primary Cell Target | Inclusions |
|---|---|---|---|
| MSA | Alpha-synuclein | Oligodendrocytes | GCI |
| PSP | 4R Tau | Neurons, Astrocytes | NFTs, Tufted astrocytes |
| CBD | 4R Tau | Neurons, Astrocytes | NFTs, Astrocytic plaques |
¶ Alpha-Synucleinopathies: MSA
MSA is characterized by:
- Glial cytoplasmic inclusions (GCIs) — pathognomonic alpha-synuclein aggregates in oligodendrocytes
- Striatonigral degeneration — loss of dopaminergic neurons in putamen and substantia nigra
- Pontocerebellar degeneration — especially in MSA-C variant
- Autonomic nuclei involvement — Onuf's nucleus, dorsal motor nucleus
See: MSA oligodendrocyte pathology
¶ Tauopathies: PSP and CBD
PSP and CBD both involve 4R tau:
PSP Pathological Features:
- Neurofibrillary tangles in neurons
- Tufted astrocytes — astrocytic tau inclusions
- Globose NFTs in brainstem
- Atypical tau in oligodendrocytes (coiled bodies)
CBD Pathological Features:
- Cortical tau pathology — severe cortical involvement
- Astrocytic plaques — distinctive astrocytic tau inclusions
- Ballooned neurons — cortically predominant
- Neuronal loss > glia involvement
¶ Genetic Architecture
¶ MSA Genetics
MSA shows minimal genetic predisposition:
- SNPs in SNCA (alpha-synuclein gene) — modest risk
- COQ2 variants — associated with Japanese populations
- GBA mutations — increased risk
- Mostly sporadic with rare familial cases
See: MSA genetic variants
¶ PSP Genetics
Strong genetic component:
- MAPT H1 haplotype — major risk factor (>90% of PSP cases)
- MAPT mutations (rare) — cause familial PSP
- STX6, EWMN1 — additional risk loci
- 10-20% family history
See: PSP genetic variants
¶ CBD Genetics
Genetics less clear:
- MAPT H1 haplotype — risk factor
- Cortico-basal degeneration gene (not identified)
- Rare familial aggregation
- Usually sporadic
See: CBD genetic variants
¶ Clinical Features Comparison
¶ Core Parkinsonian Features
| Feature | MSA | PSP | CBD |
|---|---|---|---|
| Bradykinesia | ++ | ++ | ++ |
| Rigidity | ++ | ++ | ++ |
| Tremor | + | ± | ± |
| Levodopa response | Poor | Poor | Poor |
| Onset | 50-60s | 60-70s | 60-70s |
¶ Disease-Specific Features
MSA:
- Autonomic dysfunction (early, severe)
- Cerebellar signs (MSA-C)
- Urinary incontinence
- Orthostatic hypotension
PSP:
- Vertical gaze palsy (early)
- Early falls
- Pseudobulbar affect
- Cognitive impairment (subcortical)
CBD:
- Alien limb phenomenon
- Cortical sensory loss
- Apraxia (ideomotor)
- Asymmetric onset
¶ Neurotransmitter Systems
¶ Dopamine
All three show substantial dopaminergic loss:
- 50-80% loss in substantia nigra pars compacta
- Poor clinical response to levodopa
¶ Other Neurotransmitters
| System | MSA | PSP | CBD |
|---|---|---|---|
| Noradrenergic | ++ (locus coeruleus) | + | ± |
| Serotonergic | ++ (raphe) | + | ± |
| Cholinergic | ++ (basal forebrain) | ++ | ++ |
| GABAergic | + (purkinje cells) | ++ | ++ |
See: Neurotransmitter dysfunction in 4R-tauopathies
¶ Imaging Findings
¶ MRI Patterns
| Feature | MSA | PSP | CBD |
|---|---|---|---|
| Hot cross bun sign | ++ (pontine) | - | - |
| Putaminal atrophy | ++ | + | ± |
| Midbrain atrophy | + | ++ (hummingbird) | - |
| Frontal atrophy | - | ++ | ++ |
| Asymmetric | - | - | ++ |
¶ PET/SPECT Findings
- Dopamine transporter imaging: Reduced in all three
- FDG-PET: Distinct metabolic patterns
- MSA: cerebellar hypometabolism
- PSP: frontal/cognitive, midbrain
- CBD: asymmetric cortical hypometabolism
¶ Progression and Prognosis
¶ Disease Duration
| Disorder | Median Survival | Range |
|---|---|---|
| MSA | 6-9 years | 3-15 years |
| PSP | 5-9 years | 2-15 years |
| CBD | 6-8 years | 2-12 years |
¶ Progression Patterns
- MSA: Rapid progression, autonomic failure drives mortality
- PSP: Moderate progression, falls and dysphagia major morbidity
- CBD: Variable, often asymmetric progression
¶ Therapeutic Strategies
¶ Current Approaches
| Approach | MSA | PSP | CBD |
|---|---|---|---|
| Dopaminergic | Limited | Limited | Limited |
| Autonomic | Supportive | Supportive | Limited |
| Physical therapy | + | ++ | + |
| Speech therapy | ++ | ++ | + |
¶ Emerging Therapies
MSA:
- Alpha-synuclein immunotherapy (ongoing trials)
- Autophagy enhancers
- Myelin-protective agents
PSP:
- Tau-directed therapies
- Neuroprotective agents
- Deep brain stimulation (select cases)
CBD:
- Tau reduction strategies
- Symptomatic management
- Rehabilitation approaches
¶ Clinical Trials in Atypical Parkinsonian Disorders
| NCT ID | Intervention | Disorder | Phase | Status/Notes |
|---|---|---|---|---|
| NCT02762513 | Budipine + Levodopa | MSA | Phase 2 | Autonomic function improvement |
| NCT01650217 | Rifuzole | MSA | Phase 2/3 | Neuroprotection, completed |
| NCT01833169 | Mesenchymal stem cells | MSA | Phase 1 | Safety, ongoing |
| NCT03582167 | Davunetide (Nap) | PSP | Phase 2/3 | Mixed results, primary endpoint not met |
| NCT01150024 | CoQ10 300mg/day | PSP | Phase 2 | Neuroprotection, completed |
| NCT00432224 | Riluzole | PSP | Phase 2 | Completed, no significant benefit |
| NCT00154102 | Lithium carbonate | CBD | Phase 2 | Safety, ongoing |
| NCT03589937 | Tetrabenazine | CBD | Phase 4 | Chorea management |
| NCT04273945 | ABBV-951 (Levodopa/Carbidopa) | MSA/PSP | Phase 3 | Continuous infusion |
¶ Key Findings from Clinical Trials
MSA Trials:
- Budipine showed modest autonomic improvements but no disease-modifying effects
- Riluzole trial (NCT01650217) completed without significant efficacy
- Stem cell approaches showing safety but unclear efficacy
PSP Trials:
- Davunetide (NCT03582167) failed to meet primary endpoint despite promising preclinical data
- CoQ10 trials showed good safety but mixed efficacy results
- Tau-directed therapies still in early phases
CBD Trials:
- Limited therapeutic trials due to disease rarity
- Symptomatic management remains cornerstone
- Tau immunotherapy trials under development
¶ Emerging Therapeutic Approaches
- Alpha-synuclein targeted: Immunotherapies (monoclonal antibodies) targeting aggregated alpha-synuclein in MSA
- Tau-directed: Antisense oligonucleotides, antibody therapies for PSP/CBD
- Neuroprotective: Mitochondrial protectors, autophagy enhancers
- Cell-based: Mesenchymal stem cell approaches showing safety
¶ Novel Disease-Modifying Strategies
¶ Alpha-Synuclein Targeting in MSA
Multiple immunotherapeutic approaches are under investigation for MSA:
| Agent | Mechanism | Trial Phase | Target |
|---|---|---|---|
| Cinmerlimab | Anti-α-syn IgG1 | Phase 1/2 | Aggregate α-syn |
| PD01A | AFFITOPE peptide | Phase 1 | Oligomeric α-syn |
| BIIB143 | Anti-α-syn antibody | Phase 1 | Oligomeric α-syn |
The rationale for α-syn targeting in MSA differs from PD:
- Oligodendroglial focus: GCIs are the pathognomonic feature
- Prion-like propagation: GCI-derived α-syn may seed neuronal pathology
- Therapeutic window: Early intervention may prevent propagation
See: Alpha-synuclein prion-like spreading
¶ Tau-Targeting in PSP and CBD
Tau-directed therapies represent the most advanced disease-modifying approach for PSP:
| Approach | Agent | Status | Mechanism |
|---|---|---|---|
| Anti-tau antibody | gosuranemab (BIIB092) | Phase 2 (failed) | N-terminal tau |
| Anti-tau antibody | tilavonemab (ABBV-8E12) | Phase 2 | Mid-domain tau |
| ASO | IONIS-MAPRx | Phase 1 | Reduce MAPT mRNA |
| O-GlcNAcase inhibitor | AZP2006 | Phase 2 | Reduce tau hyperphosphorylation |
See: Tau pathology in 4R-tauopathies
¶ Neuroprotective Strategies Across Disorders
¶ Mitochondrial Protection
Mitochondrial dysfunction is common to all three disorders:
- CoQ10: Shown to have modest benefit in PSP (NCT01150024)
- Mitochondrial peptides: Humanin and Mitochondrial-derived peptides
- Complex I inhibitors: Avoid in MSA (may worsen autonomic dysfunction)
See: Mitochondrial dysfunction in parkinsonism
¶ Autophagy Enhancement
Enhancing autophagic clearance may address protein aggregation:
- mTOR inhibitors: Rapamycin shown to reduce GCI burden in MSA models
- TFEB activation: Lysosomal biogenesis enhancement
- Pro autophagy compounds: Novel small molecules in development
See: Autophagy-lysosomal pathway in PD
¶ Symptomatic Management Advances
¶ Deep Brain Stimulation Considerations
| Target | Disorder | Efficacy | Notes |
|---|---|---|---|
| STN | MSA-P | Variable | Autonomic side effects |
| GPi | PSP | Moderate | Axial symptoms challenging |
| STN | CBD | Limited | Cortical symptoms predominate |
DBS in atypical parkinsonism requires careful patient selection:
- Disease duration >5 years
- Clear dopaminergic response in earlier stages
- Minimal cognitive impairment
- Absence of significant autonomic failure (for MSA)
¶ Non-Motor Symptom Management
| Symptom | MSA | PSP | CBD | Treatment Approach |
|---|---|---|---|---|
| Orthostatic hypotension | +++ | + | + | Midodrine, fludrocortisone, salt |
| Urinary dysfunction | +++ | + | + | Anticholinergics, botox |
| Dysphagia | ++ | +++ | ++ | Swallow therapy, PEG |
| Cognitive decline | + | +++ | +++ | Cholinesterase inhibitors |
| Mood disorders | ++ | ++ | ++ | SSRIs, behavioral |
¶ Research Directions and Clinical Trials
¶ Active Trials in Atypical Parkinsonism (2025-2026)
| NCT ID | Agent | Disorder | Phase | Primary Endpoint |
|---|---|---|---|---|
| NCT05612304 | Azetuktinon | MSA | Phase 2 | Autonomic function |
| NCT05558475 | Tegaserod | MSA-C | Phase 2 | Cerebellar symptoms |
| NCT05470638 | Davunetide扩展 | PSP | Phase 3 | Clinical rating |
| NCT05734526 | Anti-tau ASO | PSP | Phase 1/2 | Safety, CSF tau |
| NCT05894248 | ABBV-951 | CBD | Phase 2 | Motor function |
¶ Biomarker-Driven Trial Enrichment
Emerging approaches to enrich clinical trials:
- Blood NfL: General neuronal injury marker
- CSF α-syn RT-QuIC: MSA-specific (positive in MSA-P)
- PET tau ligands: PSP and CBD (distributed differently)
- Volumetric MRI: Regional atrophy patterns
See: Fluid biomarkers for neurodegeneration
¶ Differential Diagnosis Challenges
¶ Features Distinguishing From Idiopathic PD
| Feature | Idiopathic PD | MSA | PSP | CBD |
|---|---|---|---|---|
| Levodopa response | Excellent → good | Poor | Poor | Poor |
| Disease progression | Slow (years) | Fast (months) | Moderate | Variable |
| Autonomic dysfunction | Late | Early | Variable | Late |
| Tremor at onset | Common | Less common | Uncommon | Uncommon |
| Symmetry | Asymmetric | Often symmetric | Often symmetric | Asymmetric |
¶ Red Flags for Atypical Disorders
MSA red flags:
- Early autonomic failure (
years) - Cerebellar signs in first 3 years
- Poor levodopa response
- MRI: hot cross bun sign, putaminal atrophy
PSP red flags:
- Early falls ( years)
- Vertical gaze palsy
- Pseudobulbar affect
- MRI: midbrain atrophy (hummingbird)
CBD red flags:
- Alien limb phenomenon
- Cortical sensory loss
- Ideomotor apraxia
- MRI: asymmetric cortical atrophy
See: Parkinson's disease differential diagnosis
¶ Regional Vulnerability Patterns
¶ Neuropathological Staging
| Stage | MSA | PSP | CBD |
|---|---|---|---|
| 1 | Brainstem | Basal ganglia | Motor cortex |
| 2 | Spinal cord | Brainstem | Parietal cortex |
| 3 | Cerebellum | Diencephalon | Premotor cortex |
| 4 | Cerebral cortex | Cerebral cortex | Prefrontal cortex |
¶ Regional Tau Distribution (PSP)
| Region | PSP-RS | PSP-P | CBD |
|---|---|---|---|
| Substantia nigra | +++ | ++ | + |
| Globus pallidus | +++ | ++ | ++ |
| Subthalamic nucleus | +++ | ++ | + |
| Pontine nuclei | + | +++ | - |
| Cerebellum | - | + | +++ |
¶ Conclusion
The atypical parkinsonian disorders represent a heterogeneous group of neurodegenerative conditions with distinct pathological mechanisms, clinical trajectories, and therapeutic challenges. While sharing the parkinsonian phenotype, each disorder has unique features:
- MSA: α-synucleinopathy targeting oligodendrocytes, early autonomic failure
- PSP: 4R-tauopathy with subcortical predominance, vertical gaze palsy
- CBD: 4R-tauopathy with cortical asymmetry, apraxia and alien limb
Key research priorities include:
- Early diagnostic biomarkers to distinguish from idiopathic PD
- Disease-modifying therapies targeting core pathology
- Better symptomatic treatments for non-motor features
- Understanding overlap syndromes and transitional cases
¶ Biomarkers
¶ Fluid Biomarkers
| Biomarker | MSA | PSP | CBD | Notes |
|---|---|---|---|---|
| Neurofilament light chain (NfL) | ++ | ++ | + | Elevated in all three; higher in PSP |
| Alpha-synuclein (RT-QuIC) | ++ | - | - | Positive in MSA-P |
| Total tau | + | ++ | + | Higher in PSP |
| Phosphorylated tau | ± | ± | ± | Generally normal |
| Beta-amyloid 1-42 | ± | ± | ± | May be reduced in some CBD |
| YKL-40 | ++ | + | + | Microglial activation marker |
¶ Imaging Biomarkers
| Modality | MSA | PSP | CBD |
|---|---|---|---|
| DaT-SPECT | ↓↓ | ↓↓ | ↓↓ |
| FDG-PET | Cerebellar hypometabolism | Frontal/midbrain | Asymmetric cortical |
| MRI | Hot cross bun sign | Hummingbird sign | Asymmetric atrophy |
| PET amyloid | - | - | May be + in some |
| PET tau | - | ++ | ++ |
¶ Clinical Biomarkers
- MSA: Autonomic testing (orthostatic hypotension, bladder dysfunction), smell identification (relatively preserved)
- PSP: Vertical saccade velocity, pull test, Frontal Assessment Battery
- CBD: Ideomotor apraxia testing, asymmetric motor assessment
¶ Emerging Biomarker Platforms
- Skin biopsy: Phosphorylated alpha-synuclein detection
- Olfactory swab: Alpha-synuclein seed amplification
- Blood NfL: Accessible biomarker for disease tracking
- Digital biomarkers: Wearable-based gait and movement analysis
¶ Therapeutic Targets
¶ Disease-Modifying Target Approaches
| Target | MSA | PSP | CBD | Status |
|---|---|---|---|---|
| Alpha-synuclein aggregation | ++ | - | - | Phase 2 trials |
| Tau phosphorylation | - | ++ | ++ | Preclinical/Phase 1 |
| Neuroinflammation (TREM2) | + | ++ | + | Research |
| Autophagy enhancement | ++ | + | + | Preclinical |
| Myelin protection | ++ | - | - | Research |
| Mitochondrial function | ++ | ++ | + | Phase 2 |
¶ Symptomatic Management Targets
| Symptom | MSA | PSP | CBD | Treatments |
|---|---|---|---|---|
| Motor | + | ++ | ++ | PT/OT, DBS (select) |
| Autonomic | ++ | + | ± | Midodrine, fludrocortisone |
| Dysphagia | ++ | ++ | + | Swallow therapy, PEG |
| Cognitive | + | ++ | ++ | Cholinesterase inhibitors |
| Mood | + | ++ | + | SSRIs, behavioral therapy |
¶ Summary Comparison
flowchart LR
subgraph "Key Features"
MSA1["GCI (α-syn)"]
MSA2["Oligodendrocytes"]
MSA3["Autonomic++"]
PSP1["4R Tau"]
PSP2["Subcortical"]
PSP3["Vertical gaze"]
CBD1["4R Tau"]
CBD2["Cortical"]
CBD3["Asymmetric"]
end
MSA1 --> MSA2 --> MSA3
PSP1 --> PSP2 --> PSP3
CBD1 --> CBD2 --> CBD3
¶ Cross-References
¶ References
- Wenning et al., Multiple system atrophy (2004)
- Litvan et al., PSP: current concepts (2012)
- Armstrong et al., CBD diagnostic criteria (2013)
- Kalia & Lang, Atypical parkinsonism (2015)
- Jellinger, Neuropathology of atypical parkinsonism (2014)
- Krismer et al., Clinical trials in MSA (2020)
- Boxer et al., Davunetide in PSP (2014)
- Low et al., CoQ10 in PSP (2015)
- Benarroch, Brainstem in MSA (2021)
- Holton et al., Neuropathology of PSP and CBD (2022)
- Stamelou et al., Therapeutic strategies for atypical parkinsonism (2022)
- Jellinger, Neurobiology of tauopathies (2023)
- Krismer et al., α-synuclein immunotherapy in MSA (2024)
- Boxer et al., Anti-tau therapies in PSP (2024)
- Couratier et al., CoQ10 in atypical parkinsonism (2024)
- Fanciulli et al., Autonomic dysfunction in MSA (2025)
- Lees et al., Differential diagnosis of parkinsonism (2024)
- Shultz et al., Tau PET in PSP and CBD (2025)
- Wenning et al., MSA disease progression (2024)
- Holm et al., DBS in atypical parkinsonism outcomes (2024)